145 related articles for article (PubMed ID: 38739215)
1. Enthesitis and Dactylitis Resolution with Risankizumab for Active Psoriatic Arthritis: Integrated Analysis of the Randomized KEEPsAKE 1 and 2 Trials.
Kwatra SG; Khattri S; Amin AZ; Ranza R; Kaplan B; Shi L; Padilla B; Soliman AM; McGonagle D
Dermatol Ther (Heidelb); 2024 Jun; 14(6):1517-1530. PubMed ID: 38739215
[TBL] [Abstract][Full Text] [Related]
2. Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis.
Gladman DD; Orbai AM; Klitz U; Wei JC; Gallo G; Birt J; Rathmann S; Shrom D; Marzo-Ortega H
Arthritis Res Ther; 2019 Jan; 21(1):38. PubMed ID: 30696483
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial.
Östör A; Van den Bosch F; Papp K; Asnal C; Blanco R; Aelion J; Carter K; Stakias V; Lippe R; Drogaris L; Soliman AM; Chen MM; Padilla B; Kivitz A
Rheumatol Ther; 2024 Jun; 11(3):633-648. PubMed ID: 38498139
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials.
Merola JF; Armstrong A; Khattri S; Paek SY; Padilla B; Yue C; Photowala H; Kaplan B; Kristensen LE
J Dermatolog Treat; 2024 Dec; 35(1):2342383. PubMed ID: 38632977
[TBL] [Abstract][Full Text] [Related]
5. Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis.
Rahman P; McInnes IB; Deodhar A; Schett G; Mease PJ; Shawi M; Cua DJ; Sherlock JP; Kollmeier AP; Xu XL; Sheng S; Ritchlin CT; McGonagle D
Clin Rheumatol; 2024 May; 43(5):1591-1604. PubMed ID: 38472528
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the Phase 3 KEEPsAKE 1 Randomized Clinical Trial.
Kristensen LE; Keiserman M; Papp K; McCasland L; White D; Carter K; Lippe R; Photowala H; Drogaris L; Soliman AM; Chen M; Padilla B; Behrens F
Rheumatol Ther; 2024 Jun; 11(3):617-632. PubMed ID: 38498141
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 1 trial.
Kristensen LE; Keiserman M; Papp K; McCasland L; White D; Lu W; Wang Z; Soliman AM; Eldred A; Barcomb L; Behrens F
Ann Rheum Dis; 2022 Feb; 81(2):225-231. PubMed ID: 34911706
[TBL] [Abstract][Full Text] [Related]
8. Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study.
Mease PJ; Gladman DD; Deodhar A; McGonagle DG; Nash P; Boehncke WH; Gottlieb A; Xu XL; Xu S; Hsia EC; Karyekar CS; Helliwell PS
RMD Open; 2020 Jul; 6(2):. PubMed ID: 32665433
[TBL] [Abstract][Full Text] [Related]
9. The effect of risankizumab on achieving minimal clinically important differences in patient-reported outcomes in patients with psoriatic arthritis: results from KEEPsAKE 1 and 2.
Kristensen LE; Soliman AM; Papp K; Barcomb L; Eldred A; Östör A
J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):2120-2129. PubMed ID: 35920763
[TBL] [Abstract][Full Text] [Related]
10. Risankizumab improved health-related quality of life, fatigue, pain and work productivity in psoriatic arthritis: results of KEEPsAKE 1.
Kristensen LE; Soliman AM; Papp K; White D; Barcomb L; Lu W; Eldred A; Behrens F
Rheumatology (Oxford); 2023 Feb; 62(2):629-637. PubMed ID: 35801915
[TBL] [Abstract][Full Text] [Related]
11. Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study.
Ritchlin CT; Mease PJ; Boehncke WH; Tesser J; Chakravarty SD; Rampakakis E; Shawi M; Schiopu E; Merola JF; McInnes IB; Deodhar A
Clin Rheumatol; 2024 Jun; ():. PubMed ID: 38844682
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 2 study.
Östör A; Van den Bosch F; Papp K; Asnal C; Blanco R; Aelion J; Lu W; Wang Z; Soliman AM; Eldred A; Padilla B; Kivitz A
Rheumatology (Oxford); 2023 Jun; 62(6):2122-2129. PubMed ID: 36282537
[TBL] [Abstract][Full Text] [Related]
13. Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the Longterm Extension of a Randomized, Placebo-controlled Study (GO-REVEAL).
Kavanaugh A; Mease P
J Rheumatol Suppl; 2012 Jul; 89():90-3. PubMed ID: 22751603
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial.
Östör A; Van den Bosch F; Papp K; Asnal C; Blanco R; Aelion J; Alperovich G; Lu W; Wang Z; Soliman AM; Eldred A; Barcomb L; Kivitz A
Ann Rheum Dis; 2022 Mar; 81(3):351-358. PubMed ID: 34815219
[TBL] [Abstract][Full Text] [Related]
15. Clinical Characteristics, Disease Activity, and Patient-Reported Outcomes in Psoriatic Arthritis Patients With Dactylitis or Enthesitis: Results From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry.
Mease PJ; Karki C; Palmer JB; Etzel CJ; Kavanaugh A; Ritchlin CT; Malley W; Herrera V; Tran M; Greenberg JD
Arthritis Care Res (Hoboken); 2017 Nov; 69(11):1692-1699. PubMed ID: 28376239
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Risankizumab in Patients with Psoriatic Arthritis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Su QY; Zhou HN; Xia GM; Zhang RY; Tian HY; Su C; Liu YX; Zhang HY; Cheng T; Huo YH; Li Q; Zhang SX
Rheumatol Ther; 2024 Apr; 11(2):227-237. PubMed ID: 38302785
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of risankizumab for active psoriatic arthritis: 52-week results from the KEEPsAKE 1 study.
Kristensen LE; Keiserman M; Papp K; McCasland L; White D; Lu W; Soliman AM; Eldred A; Barcomb L; Behrens F
Rheumatology (Oxford); 2023 Jun; 62(6):2113-2121. PubMed ID: 36282530
[TBL] [Abstract][Full Text] [Related]
18. Effects of upadacitinib on enthesitis in patients with psoriatic arthritis: a post hoc analysis of SELECT-PsA 1 and 2.
Cantini F; Marchesoni A; Novelli L; Gualberti G; Marando F; McDearmon Blondell E; Gao T; McGonagle D; Salvarani C
Rheumatology (Oxford); 2024 Feb; ():. PubMed ID: 38331400
[TBL] [Abstract][Full Text] [Related]
19. Risankizumab in Adults with Psoriatic Arthritis.
Machlab K; Yeung J; Gooderham M
Skin Therapy Lett; 2023 Nov; 28(6):1-6. PubMed ID: 38015960
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1-3 studies.
Gladman DD; Kavanaugh A; Gómez-Reino JJ; Wollenhaupt J; Cutolo M; Schett G; Lespessailles E; Guerette B; Delev N; Teng L; Edwards CJ; Birbara CA; Mease PJ
RMD Open; 2018; 4(1):e000669. PubMed ID: 30018799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
